Merck & Co Inc (NYSE:MRK) Institutional Investor Positioning

Merck & Co., Inc. (NYSE:MRK) Logo

Sentiment for Merck & Co Inc (NYSE:MRK)

Merck & Co Inc (NYSE:MRK) institutional sentiment is 0.99 in 2018 Q2. Its the same as in 2018Q1. The ratio is the same, as only 663 investment managers started new or increased stock positions, while 667 reduced and sold their equity positions in Merck & Co Inc. The investment managers in our partner’s database reported: 1.87 billion shares, down from 1.90 billion shares in 2018Q1. Also, the number of investment managers holding Merck & Co Inc in their top 10 stock positions increased from 59 to 85 for an increase of 26. Sold All: 48 Reduced: 619 Increased: 535 New Position: 128.

Merck & Co., Inc. provides healthcare solutions worldwide. The company has market cap of $192.64 billion. It operates in four divisions: Pharmaceutical, Animal Health, Healthcare Services, and Alliances divisions. It has a 152.74 P/E ratio. The firm offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

The stock decreased 0.71% or $0.53 during the last trading session, reaching $74.08. About 7.69 million shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 6.72% since November 14, 2017 and is uptrending. It has underperformed by 8.90% the S&P500.

Senzar Asset Management Llc holds 18.82% of its portfolio in Merck & Co., Inc. for 107,434 shares. Srb Corp owns 1.88 million shares or 12.53% of their US portfolio. Moreover, Sector Gamma As has 9.22% invested in the company for 913,830 shares. The New York-based Healthcor Management L.P. has invested 8.06% in the stock. Krensavage Asset Management Llc, a New York-based fund reported 515,428 shares.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Ratings analysis reveals 100% of Merck \u0026 Co’s analysts are positive. Out of 7 Wall Street analysts rating Merck \u0026 Co, 7 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $74 while the high is $84. The stock’s average target of $79 is 6.64% above today’s ($74.08) share price. MRK was included in 9 notes of analysts from July 30, 2018. The company was maintained on Thursday, August 23 by Morgan Stanley. The firm earned “Buy” rating on Tuesday, October 16 by Citigroup. Credit Suisse maintained the stock with “Outperform” rating in Thursday, October 11 report. On Friday, September 7 the stock rating was maintained by Barclays Capital with “Overweight”. Citigroup maintained the stock with “Buy” rating in Wednesday, October 31 report. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Buy” rating by Bank of America on Monday, July 30. BMO Capital Markets maintained the shares of MRK in report on Monday, October 22 with “Outperform” rating. The firm earned “Buy” rating on Monday, October 29 by SunTrust. The firm has “Overweight” rating by Barclays Capital given on Friday, October 12.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: Seekingalpha.com which released: “OncoSec down 56% premarket on mid-stage TAVO data” on November 06, 2018, also Streetinsider.com with their article: “Merck (MRK) Reports Phase 3 KEYNOTE-181 Trial Investigating KEYTRUDA Met a Primary Endpoint of OS in Patients …” published on November 14, 2018, Seekingalpha.com published: “Merck’s cancer candidates MK-4280 and MK-7684 show encouraging action in early-stage studies” on November 07, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Finance.Yahoo.com and their article: “Can These 2 Battered Biotech Stocks Recover?” published on November 14, 2018 as well as Streetinsider.com‘s news article titled: “Merck (MRK) Begins Rolling Submission of Licensure Application for V920 to FDA” with publication date: November 13, 2018.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.